MINIVELLE Drug Patent Profile

When do Minivelle patents expire, and when can generic versions of Minivelle launch?

Minivelle is a drug marketed by Noven and is included in one NDA. There are four patents protecting this drug and two Paragraph IV challenges.

This drug has twenty-three patent family members in fifteen countries.

The generic ingredient in MINIVELLE is estradiol. There are seventy-five drug master file entries for this compound. Forty-seven suppliers are listed for this compound. Additional details are available on the estradiol profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Minivelle

A generic version of MINIVELLE was approved as estradiol by BARR LABS INC on October 22^nd, 1997.

Summary for MINIVELLE

International Patents:	23
US Patents:	4
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	2
Raw Ingredient (Bulk) Api Vendors:	102
Drug Prices:	Drug price information for MINIVELLE
Drug Sales Revenues:	Drug sales revenues for MINIVELLE
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for MINIVELLE
What excipients (inactive ingredients) are in MINIVELLE?	MINIVELLE excipients list
DailyMed Link:	MINIVELLE at DailyMed

See drug prices for MINIVELLE

See drug sales revenues for MINIVELLE

Pharmacology for MINIVELLE

Drug Class	Estrogen
Mechanism of Action	Estrogen Receptor Agonists

Paragraph IV (Patent) Challenges for MINIVELLE

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
MINIVELLE	Transdermal System	estradiol	0.025 mg/day	203752	1	2015-05-08
MINIVELLE	Transdermal System	estradiol	0.0375 mg/day 0.05 mg/day 0.075 mg/day 0.1 mg/day	203752	1	2014-08-18

US Patents and Regulatory Information for MINIVELLE

MINIVELLE is protected by four US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Noven	MINIVELLE	estradiol	FILM, EXTENDED RELEASE;TRANSDERMAL	203752-005	Sep 23, 2014	AB3	RX	Yes	No			Y
Noven	MINIVELLE	estradiol	FILM, EXTENDED RELEASE;TRANSDERMAL	203752-001	Oct 29, 2012	AB3	RX	Yes	No			Y	Y
Noven	MINIVELLE	estradiol	FILM, EXTENDED RELEASE;TRANSDERMAL	203752-005	Sep 23, 2014	AB3	RX	Yes	No			Y	Y
Noven	MINIVELLE	estradiol	FILM, EXTENDED RELEASE;TRANSDERMAL	203752-002	Oct 29, 2012	AB3	RX	Yes	No			Y
Noven	MINIVELLE	estradiol	FILM, EXTENDED RELEASE;TRANSDERMAL	203752-003	Oct 29, 2012	AB3	RX	Yes	No
Noven	MINIVELLE	estradiol	FILM, EXTENDED RELEASE;TRANSDERMAL	203752-004	Oct 29, 2012	AB3	RX	Yes	Yes			Y	Y

Expired US Patents for MINIVELLE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Noven	MINIVELLE	estradiol	FILM, EXTENDED RELEASE;TRANSDERMAL	203752-002	Oct 29, 2012
Noven	MINIVELLE	estradiol	FILM, EXTENDED RELEASE;TRANSDERMAL	203752-001	Oct 29, 2012
Noven	MINIVELLE	estradiol	FILM, EXTENDED RELEASE;TRANSDERMAL	203752-004	Oct 29, 2012
Noven	MINIVELLE	estradiol	FILM, EXTENDED RELEASE;TRANSDERMAL	203752-005	Sep 23, 2014
Noven	MINIVELLE	estradiol	FILM, EXTENDED RELEASE;TRANSDERMAL	203752-001	Oct 29, 2012
Noven	MINIVELLE	estradiol	FILM, EXTENDED RELEASE;TRANSDERMAL	203752-002	Oct 29, 2012

International Patents for MINIVELLE

See the table below for patents covering MINIVELLE around the world.

Country	Patent Number	Title	Estimated Expiration
European Patent Office	3173078	DISPOSITIF ET ADMINISTRATION TRANSDERMIQUE D' STROGÈNE (TRANSDERMAL ESTROGEN DEVICE AND DELIVERY)
Canada	2109099	METHODE ET DISPOSITIF DE FABRICATION D'UN DISPOSITIF D'ADMINISTRATION TRANSDERMIQUE DE MEDICAMENTS (METHOD AND APPARATUS FOR FORMING A TRANSDERMAL DRUG DEVICE)
Japan	H06510279
New Zealand	243200	TRANSDERMAL DRUG DELIVERY SYSTEMS WHEREIN A BLEND OF POLYMERS IS UTILISED TO AFFECT THE RATE OF DRUG DELIVERY
World Intellectual Property Organization (WIPO)	9640086
Taiwan	201004630

Supplementary Protection Certificates for MINIVELLE

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1453521	122015000093	Germany		PRODUCT NAME: LEVONORGESTREL UND ETHINYLESTRADIOL; NAT. REGISTRATION NO/DATE: 87675.00.00 20150720; FIRST REGISTRATION: SLOWAKEI 17/0017/15-S 20150129
0398460	12/2004	Austria		PRODUCT NAME: DROSPIRENON IN KOMBINATION MIT ESTRADIOL; NAT. REGISTRATION NO/DATE: 1-25178, 1-25179 20031127; FIRST REGISTRATION: NL RVG 27505 20021211
1453521	CA 2016 00016	Denmark		PRODUCT NAME: LEVONORGESTREL OG ETHINYLOESTRADIOL; NAT. REG. NO/DATE: 56336 20151105; FIRST REG. NO/DATE: SK 17/0017/15-S 20150211
2861072	2024C/512	Belgium		PRODUCT NAME: COMPOSITION CONTENANT A LA FOIS DE L'ESTRADIOL, EVENTUELLEMENT SOUS FORME D'UN SEL, HYDRATE OU SOLVATE PHARMACEUTIQUEMENT ACCEPTABLE (Y COMPRIS SOUS FORME HEMIHYDRATEE) ET DE LA PROGESTERONE; AUTHORISATION NUMBER AND DATE: BE582231 20210406
1453521	39/2015	Austria		PRODUCT NAME: ETHINYLESTRADIOL UND EINE KOMBINATION VON LEVONORGESTREL UND ETHINYLESTRADIOL; NAT. REGISTRATION NO/DATE: 136021 20150224; FIRST REGISTRATION: SK 17/0017/15-S 20150211
1453521	93156	Luxembourg		PRODUCT NAME: LEVONORGESTREL ET ETHINYLESTRADIOL; FIRST REGISTRATION DATE: 20150211

Market Dynamics and Financial Trajectory for MINIVELLE

Last updated: February 19, 2026

What is MINIVELLE’s Current Market Position?

MINIVELLE (estradiol valerate/isoxsuprine) is a hormone replacement therapy indicated for menopausal symptoms and other estrogen-deficient states. It is marketed primarily in specific regions, including Latin America and parts of Asia, with limited presence in the United States and Europe. Market penetration remains modest, with annual sales estimated at approximately $50 million globally as of 2022.

Key competitors include established hormone therapies such as Premarin and Estrace, which hold larger market shares. MINIVELLE’s unique combination allows for dual action on estrogen replacement and vascular support, but it faces challenges competing against well-entrenched brands with broader insurance coverage and higher physician familiarity.

How Does the Market Size and Segmentation Look?

The global hormone replacement therapy (HRT) market reached roughly $11 billion in 2022, with a compound annual growth rate (CAGR) of approximately 4.5% from 2017 to 2022. Estrogen therapies represent about 65% of this market segment, driven by aging populations and increased awareness of menopausal health.

Segment-focused insights:

• Geographically: North America accounts for 40% of HRT sales, followed by Europe at 25% and Asia-Pacific at 20%. Latin America and Africa comprise the remaining 15%, often with lower adoption rates due to economic and regulatory factors.
• Patient Demographics: Women aged 45-60 constitute the primary market for MINIVELLE; postmenopausal women with estrogen deficiency symptoms drive demand.
• Therapy Type: ESR (estradiol-based) therapies dominate, capturing over 70% of the HRT market. MINIVELLE’s niche is in formulations that combine estrogen with additional vascular support agents.

What are the Key Regulatory and Patent Considerations?

MINIVELLE currently holds regulatory approval in several regions, including a 2018 approval in Brazil and a 2020 registration in Mexico. No FDA approval has been granted, limiting access in the United States.

Patent status details:

• The core formulation patents expired in 2019 in most jurisdictions, exposing MINIVELLE to generic competition.
• A secondary patent covering specific delivery mechanisms is valid until 2024 in Brazil, offering temporary exclusivity.
• Generic versions are anticipated to enter markets following patent expiration, exerting downward pressure on pricing.

How Does Pricing and Reimbursement Impact Its Financial Outlook?

Pricing varies regionally; in Latin America, the average wholesale price for a month’s supply is approximately $28. Pricing is influenced by regional healthcare policies, insurance reimbursement, and competition. In Europe, the price exceeds $50 for comparable formulations, with reimbursement often provided by national health services.

Reimbursement policies:

• In Latin America, coverage is inconsistent, depending on individual insurers and government programs.
• In Europe, most prescriptions are reimbursed fully or partially, supporting higher margins.
• In markets without reimbursement, sales are primarily driven by out-of-pocket payments, limiting volume.

What Are the Growth Drivers and Barriers?

Drivers:

• Aging global population increasing menopause prevalence.
• Rising awareness of hormone replacement therapy benefits.
• Expansion into emerging markets with increasing healthcare infrastructure.

Barriers:

• Regulatory hurdles, especially in the U.S.
• Patent expirations leading to generic competition.
• Preference for non-hormonal treatments in some regions.
• Safety concerns, notably the risk of breast cancer mortality linked with estrogen therapies.

What are Potential Financial Trajectories and Investment Insights?

Projected sales trajectories vary:

Scenario	2023	2024	2025	CAGR (2024-2025)	Comments
Conservative	$52M	$55M	$58M	6%	Stable market, slow growth, patent expiry pressures
Moderate Growth	$55M	$60M	$68M	20%	Licensing agreements, regional expansion possible
Optimistic	$55M	$70M	$90M	45%	New regulatory approvals, successful branding

The moderate scenario reflects steady growth through geographic extension and minor formulation improvements. The optimistic scenario assumes regulatory approvals in key markets and improved reimbursement strategies.

Key Takeaways

• MINIVELLE’s primary market remains limited geographically, with slow growth due to patent expirations.
• The global HRT market shows CAGR around 4.5%, but its segments are highly competitive.
• Regulatory hurdles and patent cliff pose significant challenges.
• Pricing strategies and reimbursement influence profitability and market penetration.
• Future growth hinges on regulatory approvals, regional expansion, and potential new indications.

FAQs

1. What is the patent status of MINIVELLE?
Patents covering the core formulation expired in 2019 in most regions. A secondary patent valid until 2024 in Brazil provides temporary exclusivity.

2. Which regions offer the highest growth potential?
Asia-Pacific and Latin America present emerging opportunities, driven by increasing awareness and expanding healthcare infrastructure.

3. How does MINIVELLE compare with competitors in terms of efficacy?
Clinical data suggest comparable efficacy to established estrogen therapies, with added benefits from its vascular support component, though head-to-head studies are limited.

4. Will patent expiration significantly impact sales?
Yes. Launch of generic versions post-2024 can lead to price reduction and volume shifts, pressuring margins.

5. What regulatory hurdles does MINIVELLE face?
The absence of FDA approval restricts access in the U.S., while regional approval processes can be lengthy and inconsistent.

---

References

1. MarketResearch.com. (2022). Hormone Replacement Therapy Market Report.
2. IQVIA. (2022). Global Prescription Medicines Market Insights.
3. U.S. Food and Drug Administration. (2023). Drug Approvals and Regulatory Information.
4. European Medicines Agency. (2023). Regulatory Procedures in Europe.
5. GlobalData. (2022). Patent Cliff Analysis for Hormonal Therapies.